Keele Research Repository

Article

Alabas, OA, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Yiu, ZZN, Hampton, PJ, Reynolds, NJ, Owen, CM, Bewley, A, Laws, PM, Warren, RB, Lunt, M, Smith, CH and Griffiths, CEM (2023) Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology.

Quirke-McFarlane, S, Weinman, J, Cook, ES, Yiu, ZZN, Dand, N, Langan, SM, Bechman, K, Tsakok, T, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Barbosa, IA, Bachelez, H, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Lambert, J, Naldi, L, Puig, L, Spuls, P, Torres, T, Warren, RB, Waweru, H, Galloway, JB, Griffiths, CEM, Barker, JN, Norton, S, Smith, CH, Mahil, SK and study group, PsoProtect (2022) Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. British Journal of Dermatology.

Bechman, K, Cook, ES, Dand, N, Yiu, ZZN, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Bachelez, H, Barbosa, I, Brown, MA, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Kelly, J, Lambert, J, Lancelot, C, Langan, SM, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Moorhead, L, Naldi, L, Norton, S, Puig, L, Spuls, PI, Torres, T, Urmston, D, Vesty, A, Warren, RB, Waweru, H, Weinman, J, Griffiths, CM, Barker, JN, Smith, CH, Galloway, JB, Mahil, SK and study group, PsoProtect (2022) Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. British Journal of Dermatology.

Mahil, SK, Yates, M, Langan, SM, Yiu, ZZN, Tsakok, T, Dand, N, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Bachelez, H, Bruce, IN, Capon, F, Contreras, CR, Cope, AP, De La Cruz, C, Di Meglio, P, Gisondi, P, Hyrich, K, Jullien, D, Lambert, J, Marzo-Ortega, H, McInnes, I, Naldi, L, Norton, S, Puig, L, Sengupta, R, Spuls, P, Torres, T, Warren, RB, Waweru, H, Weinman, J, Griffiths, CEM, Barker, JN, Brown, MA, Galloway, JB, Smith, CH and CORE-UK study groups, PsoProtect (2021) Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. British Journal of Dermatology.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology.

Mahil, SK, Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Dand, N, Coker, B, Wall, D, Fletcher, G, Bosma, A, Capon, F, Iversen, L, Langan, SM, Di Meglio, P, Musters, AH, Prieto-Merino, D, Tsakok, T, Warren, RB, Flohr, C, Spuls, PI, Griffiths, CEM, Barker, J, Irvine, AD and Smith, CH (2020) Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183 (2). 404 - 406.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183 (2). 294 - 302.

Yiu, ZZN, Sorbe, C, Lunt, M, Rustenbach, SJ, Kühl, L, Augustin, M, Mason, KJ, Ashcroft, DM, Griffiths, CEM and Warren, RB (2019) Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 180 (4). 894 -901.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD and Study Group, BADBIR (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181 (6). 1265 - 1271.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Williams, S, Yiu, ZZN, McElhone, K, Ashcroft, DM, Kleyn, CE, Jabbar-Lopez, ZK, Owen, CM, Reynolds, NJ, Smith, CH, Wilson, N, Warren, RB and Griffiths, CEM (2019) Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181 (2). 256 - 264.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Smith, CH, Hampton, PJ, Lunt, M, McElhone, K, Warren, RB, Yiu, ZZN, Griffiths, CEM, Burden, AD and Study Group, BADBIR (2018) Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154 (5). 581 - 588.